<DOC>
	<DOC>NCT01516957</DOC>
	<brief_summary>The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis. Patients will randomly receive either AMG 827 or placebo (a look-a-like liquid that does not have any drug in it) and neither the doctor nor the patient will know what treatment is being given.</brief_summary>
	<brief_title>AMG 827 in Subjects With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>Subject has had a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis (CASPAR) criteria) for at least 6 months Subject has ≥ 3 tender and ≥ 3 swollen joints Subject has an active infection or history of infections (systemic antiinfectives were used within 28 days; requiring hospitalization or intravenous antiinfectives within 8 weeks; recurrent or chronic) Significant concurrent medical conditions Pregnant or breast feeding Significant Laboratory abnormalities Use of sulfasalazine, hydroxychloroquine, systemically administered calcineurin inhibitors, azathioprine, parenteral corticosteroids including intramuscular or intraarticular administration, or live vaccines within 28 days Use of antiTNF therapy within 2 months Use of an antiinterleukin (IL)12/IL23 drug or other experimental or commercially available biologic therapies for psoriasis and/or psoriatic arthritis within 3 months Prior use of rituximab Prior use of antiIL17 biologic therapy, including AMG 827</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>IL-17</keyword>
	<keyword>AMG 827</keyword>
	<keyword>AMG827</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>Spondylarthropathy</keyword>
</DOC>